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Abstract
As proton therapy increases in popularity, so does the need for effective quality assurance.
Proton therapy institutions participating in NCI funded clinical trials rely heavily on the
credentialing and auditing services of IROC-H and therefore the process must be well
understood. The purpose of this project is to understand the uncertainties in proton therapy
treatment planning for the IROC-H proton phantom QA program due to variations in CT
technique and proton energy. It was hypothesized that variations in CT technique and proton
energy will alter the delivered dose distributions of typical proton treatments by reducing the
percent of passing pixels by 10% using a gamma analysis criteria of ±3%/5mm as measured
using a heterogeneous proton QA phantom. A CT phantom used by IROC-H during therapy site
visits was scanned using three CT techniques (80, 120, 140kV) with a CT scanner used for
proton therapy simulations and irradiated with a passively scattered beam at three energies
(140, 200, 250 MeV) to measure, respectively, HU and Relative Linear Stopping Power (RLSP) in
order to create HU to RLSP calibration curves for comparison with reference curves as defined
by this study. The phantom has proton equivalent materials with a wide variety of HU and
RLSPs to allow for the creation of a calibration curve for common tissue equivalent materials.
Treatment plans were created for an anthropomorphic proton lung phantom using the various
CT technique/ beam energy calibration curves to determine the differences in the dose
distributions by performing a gamma analysis. The 3D gamma analysis resulted in a pass rate of
100% for all plans and the 2D gamma analysis resulted in a pass rate above 99%. This result
implied the varying treatment plans did not substantially affect the outcome of the dose
comparison and therefore rejects the stated hypothesis and further work is needed to
investigate the uncertainty present in this QA process.
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Chapter 1
1 Introduction and Background
1.1 Statement of Problem
1.1.1 General Problem Area
Proton and radiation therapy is continuing to grow as a radiation oncology treatment modality,
being adopted by an increasing number of institutions in the United States and around the
world. There are currently 17 clinically active proton centers in the United States with another
14 under construction and an additional 3 centers still in the planning stages [1][2][3]. As the
number of proton therapy facilities grows, so does the number of facilities seeking to
participate in the National Cancer Institute’s (NCI) funded proton therapy clinical trials and the
number of patients impacted by these proton trials. The NCI, in 2014, implemented the
National Clinical Trials Network (NCTN), a network of five clinical trial groups conducting multiinstitutional phase I, II and III clinical trials with the goal of developing new protocols,
conducting the trials and compiling data from many institutions in order to improve the
standard of care for the treatment of cancer [4]. As a part of the NCTN, the NCI funded a central
Core group to a provide quality assurance and data management service to the NCTN and their
participants. This Core group is the Imaging and Radiation Oncology Core (IROC) Cooperative.
IROC consists of 6 different radiotherapy and imaging QA centers located across the USA. One
of the QA centers is the Imaging and Radiation Oncology Core Houston (IROC-H) QA Center,
formerly known as the Radiological Physics Center (RPC). The mission of IROC-H is to ensure
consistent and comparable radiation doses are delivered by the participating institutions and
that the highest quality data is included in NCTN radiation therapy clinical trials. To accomplish
its mission, IROC-H performs dosimetry audits of institutions participating in NCI funded clinical
trials with a combination of off-site mail-in thermoluminescent dosimeter (TLD) and optically
stimulated luminescent dosimeter programs, on-site dosimetry review visits, retrospective
inspection of patient records, and trial credentialing activities that include end-to-end (E2E)
anthropomorphic phantom irradiations [5]. These dosimetry audits are performed for both
photon and proton radiotherapy facilities. Currently, IROC-H currently monitors 2040
institutions worldwide of which 17 are institutions utilizing proton therapy [5].
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The anthropomorphic phantoms used by IROC-H include phantoms designed for photon and
proton therapy. The phantoms cover various anatomical sites such as the head, head & neck,
thorax, spine, abdomen and pelvis [5]. In 2014, 627 phantoms were shipped from IROC-H to
institutions all over the world. These phantoms are used for the purpose of credentialing an
institution’s ability to use advanced radiotherapy technologies in the NCTN clinical trial setting.
Phantoms are constructed to be anatomically similar to humans, have targets and organs at
risk, have plastics that are good tissue substitutes and contain radiation dosimeters (TLD and
radiochromic film). Institutions are asked to treat the phantom as if it were a patient and to
complete the end-to-end treatment process from imaging, to treatment planning, to patient
setup, and finally treatment delivery. The phantom is then sent back to IROC-H for the
evaluation of the dosimeters.
A key component of the treatment process is the imaging phase. In both photon and proton
therapy computed tomography (CT) imaging is used for simulating and planning the radiation
treatment. CT enables the physician and dosimetrist to visualize targets, organs at risk and
tissue heterogeneities so that a conformal treatment plan may be designed. Each treatment
planning system used by an institution has a built-in calibration curve used to convert the
Hounsfield units (HU) of the CT to electron density for photon treatment dose calculations or to
relative linear stopping power (RLSP) for proton treatment range definition. These calibration
curves are essential for accurate dose distribution calculations. Any uncertainty in the
calibration curves may ultimately lead to variability in the dose delivery to a patient or one of
IROC-H’s QA phantoms. An example of a proton CT calibration curve can be seen in the curve
used clinically at MD Anderson’s PTC-H shown below in Figure 1.
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Figure 1. Proton CT Calibration curve used clinically at the PTC-H

1.1.2 Specific Problem
The use of proton therapy in NCI clinical trials requires that a proton facility first be approved by
IROC-H and then it may have to complete additional credentialing requirements depending on
the specific clinical trial. Both of these phases include the irradiation of IROC-H’s E2E proton QA
phantoms, specifically designed for use with proton therapy, to assess the facility’s ability to
deliver accurate doses to the desired location.

Proton E2E QA phantoms are designed with materials that have an HU value and RLSP that fall
on the proton calibration curve used by proton planning systems to convert HU to RLSP. A
phantom made of such materials is termed “proton equivalent.” A phantom is designated as
proton equivalent when it has an RLSP within five percent of the tissue-equivalent calibration
curve [6]. These phantoms are designed by IROC-H and the materials are tested extensively to
determine proton equivalence. It has been determined that phantom materials suitable for use
in photon beams are not always suitable for use in proton beams. For this reason IROC-H has
separate phantoms for use with photon and proton therapy quality assurance testing. IROC-H
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currently has five E2E QA phantoms that can be used for proton therapy: head, spine, thorax,
liver, and pelvis. All of these phantoms require CT imaging as a part of the E2E audit and any
variation in the HU assigned to each phantom component could lead to errors in the dose
calculation by the planning system due to variations in the calibration curve as a function of CT
technique.

Since the proton calibration curve (HU vs. RLSP) in each planning system is

determined for a single proton reference energy, changes in proton energy used to deliver
treatment could also result in dose delivery errors if the RLSP values for the new proton energy
do not match those used for the calibration curve. Variability in CT technique and proton beam
energy may play a role in the observed differences in the dose and dose distributions measured
by IROC-H’s QA phantoms as compared to the planning system calculations.

IROC-H monitors 17 institutions using proton therapy and has observed a lower phantom pass
rate for proton institutions. This low proton pass rate has raised red flags in the proton
phantom quality assurance program. The participating proton institutions receive an initial site
visit by IROC-H physicists during which their calibration curve or curves are inspected. It has
been discovered that most institutions use a single calibration curve with a minority using two
curves, but no institutions uses more than two. IROC-H believes that a proton institutions’ use
of a single reference calibration curve, created with the parameters of a single CT technique
used to determine HU and a single proton energy used to determine RLSP, may be a source of
uncertainty in the E2E quality assurance process that contributes to institutional phantom
failures. Uncertainty arises when the parameters under which the calibration curve was created
are not the same parameters as those that are used to image and irradiate the phantom
according to IROC-H’s quality assurance protocols. Moyers’ work on this subject supports the
claim that changes in the calibration curve can impact dose delivery [7].

This project will focus on the uncertainty in the proton calibration curve due to CT technique
and proton energy and how this uncertainty may translate to distributions in dose.
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1.1.3 Importance of Topic
Clinical trials are research studies involving the direct treatment of patients to test a therapy
before it becomes standard practice in the clinic. Thousands of patients are treated each year
under clinical trials and provide data to determine the effectiveness of various cancer
treatment approaches. New technology and methods would not be able to be utilized without
first being subject to clinical trial research. In this way clinical trials are vital to moving forward
in the successful detection and treatment of cancer.

In 2014, over 19,000 patients participated in NCI clinical trials conducted by 14,000
investigators at 3,100 different institutions [8]. This massive aggregate of data is only useful if
the programs and protocols deliver treatment accurately and consistently. A large portion of
these trials involve radiation therapy and must be monitored regularly to maintain the
necessary quality of data to be used in cooperative clinical trial studies. IROC is instrumental in
credentialing and monitoring these institutions and makes it possible for trials to successfully
accomplish their goals.

The goal of this study is to better understand the uncertainty in the measures used by IROC-H
for determining the quality of an institution’s proton therapy delivery. A better understanding
of this uncertainty will result in a higher level of confidence for the use of the phantom services
for proton QA. This study is focusing on the uncertainty associated with the calibration curve
used by the treatment planning system to convert CT number, or HU, of the images used for
planning to the RLSP of protons to determine the desired energy to be deposited by the
protons in a particular tissue.

As previously discussed, many proton institutions monitored by IROC are using a single
calibration curve regardless of simulation and treatment parameters. The use of a single curve
has the potential to cause errors in dose distribution during an IROC-H phantom irradiation if
the parameters used are not those that were used to develop the calibration curve. This
discrepancy could lead to a material being shifted on the calibration curve, which could cause
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the treatment planning system to incorrectly calculate the range of the protons and dose to be
delivered to a particular material in the phantom.

In addition to monitoring clinical trial participants and their ability to provide correct trial data,
IROC-H has also been successful at detecting and preventing radiation incidents [9][10], thus
playing a role in patient safety. Proton therapy utilizes the Bragg peak behavior of protons in
which a very large percentage of energy is deposited at the distal end of the proton’s path. Due
to these high doses and steep dose gradients involved in proton therapy, accidents have the
potential to cause more harm to patients than photon therapy, furthering the need for
independent quality assurance checks by institutions such as IROC-H and their QA phantoms.
This safety aspect enhances the incentive to reduce the uncertainty in IROC-H’s proton
phantom program.

1.2

Hypothesis

The hypothesis of this project is as follows:

Variations in CT technique and proton energy will alter the delivered dose
distributions of typical proton treatments by reducing the percent of passing pixels
by 10% using a gamma analysis criteria of ±3%/5 mm as measured using a
heterogeneous proton QA phantom.

The specific aims to test this hypothesis are:

1. Measure the RLSP of designated materials and create custom HU vs. proton RLSP curves
for 3 commonly used CT techniques and 3 proton energies.
2. Create a treatment plan for a heterogeneous proton QA phantom with a standard
treatment planning system HU vs. RLSP calibration curve. Then create nine treatment
plans for the same QA phantom using the three CT image datasets.
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3. Incorporate custom proton energy dependent calibration curves determined in Aim 1
into the treatment planning system and estimate the change in dose coverage due to a
change in proton energy. Analyze the plan differences with a gamma analysis.

1.3 Literature Review
1.3.1 Proton background
1.3.1.1 History
The discovery of the proton is credited to Ernest Rutherford for his published experiments in
1919 in changing one element to another titled “Collision of Alpha Particles with Light Atoms”
in which he identified a hydrogen nucleus [11]. Protons have since been discovered to be
particles in the nucleus of every atom with a positive charge of 1.602 *10-19 Coulombs and a
mass of 1.673*10e-27 kg.

The use of protons for therapeutic purposes was first proposed by Robert Wilson in 1946 in his
paper “Radiological Use of Fast Protons” [12]. He suggested that the new technology that
allowed for the acceleration of protons to higher energies enabled charged particles to
penetrate bodies for medical uses.

From the early 1950’s to 1990 proton therapy began to grow as an idea for therapy and
patients began to be treated at physics laboratories around the world [13]. In 1990, the nation’s
first hospital-based accelerator used for proton therapy opened at Loma Linda University
Medical Center [14][15]. The field has continued to grow in the years since and there are now
17 proton therapy facilities in operation throughout the United States having treated over fifty
thousand patients [1].

M.D. Anderson Cancer Center’s (MDACC) proton therapy center - Houston (PTC-H) became
clinically active in 2006 and has three rotating gantries, two providing passive scattering beams
and one providing a pencil beam scanning option, and a fourth treatment room with two fixed
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beamlines [16]. The center has the capability of treating patients with energies up to 250 MeV.
This project was completed at the MDACC PTC-H.

1.3.1.2 Proton behavior
Protons are valuable for therapeutic use because of their unique behavior in tissue. Protons can
interact via coulomb, elastic, or inelastic interactions. Protons primarily lose energy via coulomb
interactions with the outer electrons of target atoms. This loss of energy is described by the
continuous slowing down approximation (CSDA). As a proton interacts with particles it loses
energy as a first approximation to the inverse of the proton’s velocity squared. As the proton
slows down more and more, this causes the majority of a proton’s energy to be deposited at
the distal end of its range. The mass stopping power is described by the Bethe Bloch equation
which is approximated below [17].

𝑆(𝐸)
𝜌

=

4𝜋𝑟𝑒2 𝑚𝑐 2 1 𝑍𝑧 2 𝐿(𝛽)
𝛽2

𝑢

𝐴

( Equation 1 )

In this formula, the following variables are defined:
S(E) Linear stopping power
re

Radius of an electron

m

Mass of an electron

c

Speed of light

β

Particle velocity/ speed of light

u

Atomic mass unit

Z

Atomic number

z

Charge of a proton

L(β) Stopping power
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The large characteristic deposition of energy at the end of the range of a monoenergetic proton
beam is called a Bragg peak after William Henry Bragg who discovered it in 1903 [18]. Bragg
peaks can be used to deposit a large dose in a tumor while sparing surrounding tissue because
of the steep falloff of the dose gradient. The range of the protons and therefore the depth of
energy deposition can be manipulated by changing the energy of the protons to better conform
to a disease site.

Bragg peaks can be further manipulated with the use of a spread out Bragg peak (SOBP) to
deliver a uniform dose over a specified distance. A range modulation wheel as pictured in
Figure 2 is used to create this plateau of dose at the desired depth. A range modulation wheel is
made of steps of varying absorber thickness to alter the range and intensity of protons passing
through as the RMW rotates rapidly. This has the effect of creating many Bragg peaks that are
superimposed to create a uniform dose across the tumor.

Figure 2. Range Modulation Wheels used at PTC-H [17]
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A comparison of proton and photon depth dose profiles reveals the benefits of using protons
therapeutically and can be visualized through their depth dose curves shown in Figure 3. Two
apparent advantages of the proton profile are the uniform maximum dose and the steep dose
falloff at the distal end of the range. While this steep gradient provides the advantage of
sparing normal tissue, it also requires very precise localization of the SOBP so as to not deliver a
very high dose to the normal tissue. Contrastingly, photons have a maximum dose at a shallow
depth and a decreasing but relatively high distal dose.

Figure 3. Depth Dose Comparison of Proton and Photon Therapy [19]

1.3.1.3 Radiobiology
Protons and other heavy ions have the advantage of having a relative biological effectiveness
(RBE) greater than that for photons. RBE is defined in Equation 2.
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𝑅𝐵𝐸 =

𝐷𝑜𝑠𝑒 𝑜𝑓 𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑒 𝑟𝑎𝑑𝑖𝑎𝑡𝑖𝑜𝑛 𝑡𝑜 𝑝𝑟𝑜𝑑𝑢𝑐𝑒 𝑎𝑛 𝑒𝑓𝑓𝑒𝑐𝑡
𝐷𝑜𝑠𝑒 𝑜𝑓 𝑡𝑒𝑠𝑡 𝑟𝑎𝑑𝑖𝑎𝑡𝑖𝑜𝑛 𝑡𝑜 𝑝𝑟𝑜𝑑𝑢𝑐𝑒 𝑎𝑛 𝑒𝑓𝑓𝑒𝑐𝑡

( Equation 2 )

The reference dose is generally defined to be 60Co and protons are clinically defined to have an
RBE of 1.1, compared to an RBE of 1.0 for photons and electrons. This implies that for the same
biological effect, 10% less physical dose will be needed with protons than with photons or
electrons. For this reason proton dose is often expressed in terms of Cobalt Gray Equivalent
(CGE) which is defined in Equation 3.

𝐶𝐺𝐸 = 𝐷𝑜𝑠𝑒𝑝𝑟𝑜𝑡𝑜𝑛𝑠 ∗ 1.1

( Equation 3 )

In Equation 3, Doseprotons is the physical dose of the protons.

1.3.2 Proton beam
The PTC-H has the capability of producing both passively scattered and pencil beam spot
scanning proton beams. This project focuses on passive scattering. PTC-H uses the double
scatter technique to create the passive scatter beam using a series of nozzle components that
include a first scatterer, a RMW, a second scatterer, a range shifter, an aperture, and a
compensator as shown in Figure 4. All of these components may be altered to modify the
beam. The first scatterer serves to spread the beam laterally while the second scatterer serves
to flatten the beam, creating a uniform energy across the entire beam [20]. A rendering of the
nozzle can be seen below.
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Figure 4. Passive scatter nozzle from PTC-H [16]

To be therapeutically useful, protons must be accelerated to very high energies with a
cyclotron, synchrotron, or synchrocyclotron. The PTC-H uses a synchrotron system. This consists
of a linac injector that generates the proton beam and accelerates it to be funneled into the
synchrotron ring where it is further accelerated to the desired energy then extracted to be used
in an individual gantry for a patient [16].

Pencil beam scanning, though a growing area of proton therapy, is not utilized in this project
and will not be discussed here.

1.3.3 CT calibration
Proton therapy is able to effectively treat conformal tissues because of the use of computed
tomography (CT) imaging. CT images serve as the input to treatment planning systems that
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enable the creation of a conformal plan to treat the tumor and spare normal tissue by
accounting for these heterogeneities.

The process of patient treatment of an IROC-H phantom audit begins with CT simulation in
which the patient or phantom is imaged with CT to be used for planning on. These images are
imported into the facility’s treatment planning system at which point the system uses a
predefined calibration curve to convert HU, the data from the CT image, to RLSP, the energy to
be deposited by the protons. This calibration can be determined in one of two ways, with the
stoichiometric method, or with the tissue substitution method.

The CT number, or HU, is defined in Equation 4.

𝐻𝑈 = 1000 ∗

µ𝑚𝑎𝑡𝑒𝑟𝑖𝑎𝑙 −µ𝑤𝑎𝑡𝑒𝑟
µ𝑤𝑎𝑡𝑒𝑟

( Equation 4 )

In Equation 4 µmaterial is the linear attenuation coefficient of the material being analyzed and
µwater is the linear attenuation coefficient of water [7]. HU is a convenient way to quantitatively
describe how a material attenuates x-rays in a CT image.

The second factor used in the calibration curve is the RLSP of the protons. This is a measure of
how protons deposit energy in a particular material relative to that of water.

1.3.3.1 Stoichiometric method
Although not used for this project, it is worth noting that the stoichiometric method has been
shown to be more accurate than the tissue substitution method and is the method used by the
PTC-H [21][22][23]. The stoichiometric method examines the problem that tissue equivalent
materials are not always sufficiently close in composition to yield accurate RLSP values for
patient tissues. This method seeks to correct for the differences in elemental composition
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between tissue substitutes and real tissues. This is accomplished by parameterizing the HU
values into a scaled HU with photoelectric, coherent scatter, and incoherent scatter
components [24]. The dependence of attenuation is fit as a function of atomic number as
shown in Equation 5. This can be done for any tissue substitute with a known composition and
density.

𝐻𝑈𝑠𝑐𝑎𝑙𝑒𝑑 = 𝜌𝑒 (𝐴𝑍 3.62 + 𝐵𝑍1.86 + 𝐶)

( Equation 5 )

In Equation 5 ρe is the electron density, Z is the atomic number, and A is a photoelectric
component constant, B is a coherent scatter component constant, and C is an incoherent
scatter component constant.

1.3.3.2 Tissue substitution method
The tissue substitution method is the original method of determining the calibration curve. In
this method, a variety of materials determined to be tissue equivalent are scanned and
irradiated to determine their HU and RLSP. This curve can then be imported into the treatment
planning system to be used to correct for heterogeneities in patient plans. The RLSP is
calculated using the Bethe-Bloch formula described previously. The Moyers et al. describes the
creation of a calibration curve with a large number of materials and outlines a simplistic
alternative for RLSP calculations. Moyers defines the RLSP in Equation 6.

𝑅𝐿𝑆𝑃 =

𝑅90,𝑤𝑎𝑡𝑒𝑟 −𝑅90,𝑚𝑎𝑡𝑒𝑟𝑖𝑎𝑙
𝑡𝑚

( Equation 6 )

R90,water is the depth to distal 90% ionization in the water phantom by itself and R 90,material is the
depth to distal 90% ionization in the water phantom with the slab of material in front. t m is the
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thickness of the slab and must be known very precisely in this calculation to yield accurate
results [7].
1.3.4 Gamma Analysis
The comparison of measured and calculated dose distributions is a critical part of
commissioning and quality assurance on treatment planning systems. Daniel Low developed a
technique that provides a quantitative measure of this comparison that can be displayed and
analyzed where this had previously not been possible. He termed this measure the gamma
index and this method was used in this study to compare dose distributions.

Low’s method uses an elliptical surface to take into account both dose difference and distance
to agreement (DTA) metrics when comparing distributions. Criteria for both dose difference
and DTA are inputs into the calculation and determine the size and shape of the ellipsoid used.
Dose difference is emphasized in regions of uniform dose while DTA is emphasized in regions of
steep dose gradients. The ellipsoid is centered on a measured point to be tested and if the
measured value is found on this surface the point is considered “passing” [25][26]. Figure 5
shown below was developed by Low and gives a geometrical presentation of the dose
difference and DTA applications independently for both 2D and one dimensional (1D),
respectively, and Figure 6 is Low’s geometrical presentation of how these metrics work
together, again in 2D and 1D, respectively.
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Figure 5. Geometrical representation of dose difference and DTA [20]

Figure 6. Geometrical representation of both dose difference and DTA [20]

In these representations, the following variables are used:
ΔDM: Dose-difference criterion
ΔdM: DTA criterion
Dm(rm): Measured dose
Dc(rc): Calculated dose
δ(rm,rc): Difference between measured and calculated doses
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The gamma index is quantitatively defined in Equation 7 below. A γ≤1 is considered “passing,”
while a γ>1 is considered “failing.”

𝛾 (𝑟𝑚 , 𝑟𝑐 ) = √

𝑟 2 (𝑟𝑚 ,𝑟𝑐 )
2
𝛥𝑑𝑀

+

𝛿 2 (𝑟𝑚 ,𝑟𝑐 )
2
𝛥𝐷𝑀

( Equation 7 )

The method described here was developed to compare two dimensional (2D) measured dose
distributions to dose distributions calculated by a treatment planning system. IROC-H has a
need to compare 2D dose distributions from film and three dimensional (3D) dose
measurements and performs a registration and gamma analysis using an open source program
called A Computational Environment for Radiotherapy Research (CERR). CERR uses the Matlab
language and is widely used to share radiotherapy data results in an easily accessible format.
The goal of this study is to compare 3D dose calculations against other 3D dose calculations
which has recently been made possible with upgrades in the CERR software to include 3D
gamma analysis.

38

Chapter 2

2

Materials and Methods

2.1 Phantoms
2.1.1 Proton CT Phantom
The proton CT phantom shown in Figure 7 was created by IROC-H while searching for
“proton equivalent” materials to be used for QA purposes. All materials in the phantom
were measured to have RLSP’s within 5% of the proton CT calibration curve used clinically at
the MD Anderson Proton Center. It contains inserts of materials all measured to be “proton
equivalent” including water, polyethylene, balsa wood, blue water, PRESAGE®, and
Techtron® HPV [6]. These materials span a wide range of HU and RLSP’s on the curve and
are intended to be utilized to create a reasonable fit with only a small number of materials.
Currently IROC-H end-to-end audit procedures utilize anthropomorphic phantoms with
materials that are not always “proton equivalent.” This requires institutions to override
RLSPs for certain materials, which does not allow the accurate assessment of the calibration
curve and may introduce errors in the dose calculations. The proton CT phantom is
currently used by IROC-H to verify consistency of calibration curves used by proton facilities
participating in NCI-funded proton therapy clinical trials.
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The proton CT phantom was used in this project as the standard for creating calibration
curves to be used for analyzing the differences in curves with varying proton parameters.

Polyethylene

Water

Balsa Wood

Blue Water

Air

PRESAGE®

HPV

Figure 7. Proton CT Phantom

2.1.2 Proton lung phantom
In 2011 Tony Blatnica modified an existing IROC-H thorax phantom that was used for
photon stereotactic body radiation therapy (SBRT) to be more “proton equivalent” so
that it could be sent out to proton institutions for approval/credentialing purposes. The
need for the modification stemmed from the lack of proton equivalent materials and
air gaps in the existing dosimetry insert that created difficulties in characterizing the
insert in a proton beam [27]. Blatnica utilized the existing base phantom and created a
new dosimetry insert using balsa wood as a verified lung equivalent material to replace
the cork that was previously being used. In 2013 Jim Neihart developed a new lung
phantom as shown in Figure 8 that was completely proton equivalent. This new
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phantom retained the insert designed by Blatnica and received a new phantom base,
ribs and heart made of materials more suitable for use in a proton beam as well as the
addition of an intra-fractional respiratory motion simulation capability.

Figure 8. Proton Lung Phantom

The proton lung phantom designed by Neihart pictured above in Figure 8 is currently in
use by IROC-H for proton quality assurance assessments and is the lung phantom used
in this project. The phantom is designed to simulate a single lung, deemed sufficient
due to the fact that most lung tumors are treated with a single lateral field and a single
oblique or anterior field, thus there was no need to provide a contralateral lung. The
phantom is comprised of five proton equivalent tissue simulating materials. To simulate
lung, soft tissue, heart tissue, tumor, and bone, the phantom uses respectively balsa
wood and cork, solid water, blue water, high impact polystyrene, and Techtron® HPV
Bearing grade plastic [28]. These materials were all measured to be within IROC-H’s
“proton equivalent” criteria, that is to be within 5% of M.D. Anderson Cancer Center’s
Eclipse HU vs. RLSP CT calibration curve [6].
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2.2 CT scans
2.2.1 CT Scanner Constancy
HU values of the materials in the proton CT phantom were measured on the clinical CT
simulation scanners at MD Anderson’s PTC-H and Ambulatory Clinical Building (ACB). To
ensure the reliability of HU measurements, multiple measurements were taken at
varying intervals on the scanners to confirm the constancy of the output. The CT
phantom was scanned (see Figure 7) and HU was measured for five consecutive days
and then on a weekly basis for five weeks. The CT scans were performed on the two CT
machines with parameters shown in Table 1:

Table 1. Parameters of CT Constancy Scans
Parameter

GE Lightspeed

GE Lightspeed

(Located in PTC-H)

(Located in ACB)

kV

120

120

Pitch

1.375:1

1.5:1

Extent

S50mm-I50mm

S50mm-I50mm

Beam

16x0.625

4x1.25

No. of Images

41

41

Beam collimation

10 mm

5 mm

Speed

13.75 mm/rot

7.5 mm/rot

Matrix size

512

512

Reconstruction

Standard

Standard

DFOV

50 cm

50 cm

SFOV

Large

Large

Rotation speed

0.8 sec

1.0 sec

Configuration

The setup for the scans is pictured in Figure 9.
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Figure 9. Setup of CT phantom in CT simulator

The resulting scans were loaded into the iSite (Philips, Amsterdam, The Netherlands)
interface created by Philips where it was possible to create ROI’s and measure the
average HU as shown in Figure 10. Because all measurements were taken with this
software, consistency between GE equipment and Philips viewing software is not of
concern.
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Figure 10. Measurement of HU

2.2.2 HU measurement
Institutions participating in proton audits by IROC-H at this time are using both 120 and
140 kV, with a majority using 120 kV when imaging the proton lung phantom during
the CT simulation step of the audit process. These energies were therefore both
included in this study, with 80 kV being included because of the possible future use of
dual energy. Dual energy CT (DECT) is gaining momentum as a modality for simulations
[29] and most methods of DECT use 80 kV as the lower energy used for increased
contrast [30]. In the event that institutions participating in IROC-H QA begin using DECT
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for simulations, it is valuable to understand how this change could affect the random
uncertainty in the IROC-H QA process. It is also valuable to include this large range of
CT techniques used to evaluate worst case scenarios for criteria used by institutions, in
the event that an institution may be trying to simulate a special procedure involving
uncommon criteria.
CT scans were taken of the proton CT phantom using 3 different CT techniques, 80 kV,
120 kV, and 140 kV to investigate changes in the proton CT calibration curve as a
function of CT technique. For each CT beam quality, ten scans were taken of the proton
CT phantom and the HU of each phantom material was averaged for a given energy to
input into a unique proton CT calibration curve.
2.3 Determination of Proton RLSP
2.3.1 Tissue substitution method
The RLSP of each material in the proton CT phantom was determined using the tissue
substitution method described by Moyers using a passive scatter proton beam on
gantries 1 and 2 at the PTC-H. This method was introduced in the previous chapter.
To determine the RLSP for a material using this method, a slab of the material is placed
in front of a water phantom and central axis depth dose curve measurements with the
beam passing through the material are taken with an ionization chamber. A second
depth dose curve in water only is measured without the material in the proton beam.
RLSP is then calculated according to Equation 6 as previously defined.

An electronic caliper was used to measure the average thickness of each measureable
material in the CT phantom as detailed below in Table 2.

Table 2. Thickness of CT phantom materials
Material
Polyethylene
Balsa wood
Blue water
HPV

Average Thickness [cm]
7.0167 ± 0.0099
7.0037 ± 0.0018
7.0087 ± 0.0008
6.9690 ± 0.0080
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Presage®

6.9200 ± 0.0066

Instead of using a water phantom and ionization chamber as Moyers suggested, this
project used a Zebra multi-layer ion chamber (MLIC) (IBA, Bartlett, USA) designed to
simulate a water phantom to determine proton depth dose curves. The Zebra is an
MLIC produced by IBA for high precision particle therapy dosimetry and is shown in
Figure 11.

Figure 11. Zebra MLIC

It is comprised of 180 plane parallel ionization chambers spaced 2 mm apart with a
removable 1 mm WET buildup block to increase the resolution of measurements [31].
The buildup screen was not used in this experiment because there was not a need for
the increased precision of measurements. Each proton CT phantom material was
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placed in the beam path near the front window of the Zebra to acquire the data to
create the proton depth dose curves with the material in place.

The Zebra utilizes the OmniPro-Incline software, also produced by IBA, for the
measurement and analysis of depth dose curves. The software allows the user to
manually select the plateau region as well as manually defining the background
locations on the depth dose profile in order to calculate the R90 that can be used in the
RLSP calculation. These defined areas can be seen below in Figures 12 and 13 and the
resulting compilation of depth dose profiles measured by the Zebra and reported by
Incline can be seen in Figure 14.

Figure 12. Selection of plateau in Incline
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Figure 13. Selection of background in Incline
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Figure 14. Depth Dose Profiles Measured by Zebra and Analyzed by Incline

At low proton energies, such as the 140 MeV beam used for this project, the SOBP is
very shallow and can be only partially measured by the Zebra when the proton
equivalent materials are placed in front of the Zebra. Because of this specific issue, the
R90,material had to be manually determined from the incomplete measured SOBPs for
blue water, Presage®, bone equivalent, and polyethylene to calculate the 140 MeV
RLSP measurements.

Three sets of RLSPs were calculated using Equation 6 as previously defined for each
material with each set corresponding to a specific proton energies, 140, 200, and 250
MeV.

2.4

Creation of custom calibration curves
Nine separate custom HU to RLSP proton CT calibration curves were created using three
different CT techniques and 3 different proton energies. 7 different materials were
measured for HU and corresponding RLSP under each of the 9 different sets of conditions.
An example of a curve plotting HU against RLSP is shown below in Figure 15 for a single CT
technique and proton energy pair, with each point representing a material from the proton
CT phantom. All nine of the custom curves created can be found compiled in Chapter 3 and
individually in Chapter 5.
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CT Calibration Curve
2
1.8
1.6
1.4

RLSP

1.2
1
0.8
0.6
0.4
0.2
0
-1500

-1000

-500

0

500

1000

1500

2000

HU

Figure 15. CT Calibration Curve for 120 kV CT technique and 140 MeV proton energy

Each generated proton CT calibration curve was imported into the Eclipse treatment
planning system (Varian, Palo Alto, CA) to be used during treatment planning. The curves
were imported manually, one point at a time. To be used by the treatment planning system,
the curves were modified by extending to the minimum and maximum HU values in order
to be read by the planning system software. It was assumed that all values above 1500
would have the same RLSP and so the curve was extended to the maximum HU, 3071, at
the same RLSP to ensure the inclusion of every pixel above 1500 HU in the treatment plan.
This same method was also employed at the low end of the HU spectrum. The curve was
extended to the lowest possible HU value, -1024, and defined with the same RLSP as air in
order to ensure the inclusion of all pixels with HU values below that measured for air.

In addition to the extension of each curve to meet Eclipse requirements, the curves were
also altered to have only increasing values to meet Eclipse requirements. The curves specific
to the 250 MeV proton energy already had this feature, but the curves specific to 140 and
200 MeV were altered to fit this requirement due to the RLSP of polyethylene being higher
than its adjacent material, water. This was accomplished through an HU override feature
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available in the Eclipse treatment planning system. This method involved defining 4 new
contours for each plan that used a curve specific to 140 or 200 MeV. The region to be
redefined was the area under the curve starting from the HU at which the curve first has an
RLSP equal to unity up to the HU at which the curve has an RLSP equal to unity for a second
time (the point defined by water). This region was divided into 4 sub-regions based on the
maximum RLSP and half of the maximum RLSP. A thresholding tool was used to define four
contours (labeled Override1 through Override4) that encompassed all of the pixels with HU
defined in these sub-regions.

The average RLSP of each of the four regions was determined and the corresponding HU for
the region of the curve in which HU > 0 was used to override the originally assigned HU
value. In this manner the RLSP on the calibration curve in the entire region being redefined
could be set as unity to satisfy the requirement of Eclipse because all HU values in this
region have been redefined as described for the purposes of dose calculations. An example
of these Override contours for the plan utilizing the 120 kV, 140 MeV calibration curve is
shown below in Figures 16-18.

In reality, Eclipse will not allow any points on the CT calibration curve to have the same RLSP
or HU, so 0.001 was added or subtracted from RLSP values as necessary to fulfill this
requirement. This was determined to not be a significant source of uncertainty in the results
of this project.

51

Figure 16. Contours for CT Overrides at Isocenter in Axial View

Figure 17. Contours for CT Overrides at Isocenter in Coronal View
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Figure 18. Contours for CT Overrides at Isocenter in Sagittal View

All 9 curves were loaded separately into the Eclipse treatment planning system under beam
administration to be available for application to any treatment plan in the Research Eclipse
system.

2.5

Treatment planning
The Research Eclipse treatment planning system at PTC-H was used for all treatment
planning in this project. Nine treatment plans were created for the proton lung phantom,
with one plan for each of 9 calibration curves created using varying combinations of CT
technique and proton energy as described previously. The three data sets taken of the
proton lung phantom with the CT simulator were used for treatment planning. Data sets
were taken at three CT techniques: 80, 120, and 140 kV.
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In this study, treatment plans using a calibration curve created with a specific CT technique
were planned on the data set created at that same CT technique (for example, all plans that
use a calibration curve created with a 120 kV CT technique will be planned on the 120 kV
data set acquired as described in previous sections).

All plans were created using a proton energy of 140 MeV because it a typical energy used by
institutions performing these lung phantom audits. Planning at the 200 and 250 MeV proton
energies was not pursued in this project due to practical issues of the phantom size and
design. Higher energies would not allow the SOBP to easily be placed at the target in the
phantom without additional manipulation.

All plans were created with the following contours: Body, Lung, Heart, PTV, Target, and TLD.
4 additional CT override contours were created for each plan using a CT calibration curve
made using 140 or 200 MeV protons. An example of all of these contours can be seen below
in Figure 19 in the plan created for use with the 120 kV / 140 MeV CT calibration curve.

Figure 19. Contours used in treatment planning
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Institutions participating in previous proton audits have created treatment plans with a
variety of beam arrangements. The beam arrangement chosen for this project is a common
orientation used by institutions and is the most easily reproducible for irradiations of the
phantom. This study chose to create all plans with two fields, an AP beam at 0° and a left
lateral beam at 90°. A compensator and block was created for each beam. Table 3 outlines
parameters in every plan used for the purposes of treatment planning. All plans have
identical parameters with the exception of CT dataset and CT calibration curve.

Table 3. Treatment planning parameters
Proton energy

140 MeV

Distal margin

0.6 cm

Proximal margin

0.3 cm

Reference point

Target

Nominal SAD

270 cm

Technique

Double Scattering

Machine

G2

Isocenter

(-0.34 cm, -3.10 cm, 1.85 cm)

Snout size

Medium

SOBP width

4.0 cm

Field 1 Nominal range

9.88 cm

Field 2 Nominal range

8.76 cm

Plan normalization value

97.00

Total dose

600 cGy

Fractions

1
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2.6 Dose comparison
2.6.1 Dose Volume Histogram (DVH) Comparison
DVH’s compare the percent volume of a specified structure that receives a given dose.
These are useful in maintaining safe and effective radiation treatments for patients
because they allow the monitoring of specific organs and regions. Target regions can be
monitored to ensure they receive an acceptably high dose and organ doses can be
monitored to ensure they remain acceptably low to avoid any adverse effects to the
patient.
The DVH relationship is used in this study to ensure the created treatment plans are
clinically viable and meet any clinical constraints. It also provides an additional way to
compare the 9 treatment plans created for this study.
2.6.2 Gamma Analysis
2.6.2.1

3D Gamma Index Analysis

The primary goal of this study was to compare the dose distributions of treatment
plans created using the different CT calibration curves created under varying
parameters outlined above. The comparisons were made between the various
treatment plan volumetric dose distribution data sets assessing agreement using a 3D
Gamma Index analysis tool with a ±3%/5mm criteria. This is problematic for the original
CERR program, but updates to the software have incorporated the ability to compare
two 3D dose files.

From the Eclipse treatment planning system it is possible to export a DICOM RT dose
file. Because CERR can only read one dose file at a time, it must be exported as a single
total dose and not individual dose files from each field. CERR has the capability of
converting these files, which are exported as DICOM files, into matlab files.

This study compared multiple plans to a single reference plan. This reference plan was
defined as the plan created with a CT calibration curve corresponding to the CT scan
using 120 kV and a proton energy of 140 MeV. This plan was chosen as reference
because these parameters are the most appropriate clinically and most widely used for
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the proton lung phantom due to its size and composition. A total of 8 comparisons to
the reference plan were made using CERR’s 3D gamma index analysis tool.

To perform a 3D gamma analysis in CERR the reference dose file must be converted
from a DICOM RT file to a matlab file and can then be imported into the CERR viewer.
Then each successive DICOM RT dataset for each treatment plan is imported and CERR
gives the user the option to choose individual plans for 3D gamma comparison. The 3D
gamma function provides the user with gamma statistics as well as a visual
representation of the gamma results which can be found in the Appendix of this report.
2.6.2.2

2D Gamma Index Analysis

In addition to a 3D gamma analysis, a 2D gamma analysis was also performed between
the reference plan axial, coronal and sagittal slices going through the isocenter and the
corresponding slices for each of the other eight plans. The same gamma analysis
criteria of 3%/5mm was used for these comparisons. This 2D evaluation was performed
because the IROC-H anthropomorphic proton phantoms use radiochromic films in the
sagittal, coronal and axial planes to measure the dose distribution delivered to the
phantoms and to compare to the dose distribution calculated by the institution’s
treatment plan. Because the film is planar, the only comparisons that can be done are
2D gamma analyses. Therefore it was necessary to mimic how the proton phantoms are
actually used and analyzed to determine whether the variations in CT technique and
proton beam energy tested would have any impact on the phantom/institution
comparison results. This 2D analysis was also of interest to show differences between
the 3D gamma analysis versus the 2D gamma analysis because it has been shown that
3D gamma analyses result in a higher pass rate than 2D gamma analyses [32].

The 2D gamma analysis was performed with the OmniPro I’mRT software created by
IBA. The region of interest (ROI) was tightened to contain only the target and adjacent
low dose regions to avoid the skewing of the results from including a high number of
pixels with very low dose. This was performed for a plane at isocenter in all three
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spatial planes, axial, coronal and sagittal. An example of the ROI chosen can be seen
below in Figures 20-22.

Figure 20. 2D gamma analysis of axial slice at isocenter comparing the study reference plan to
the plan corresponding to 140 kV and 250 MeV.

Figure 21. 2D gamma analysis of coronal slice at isocenter comparing the study reference plan
to the plan corresponding to 140 kV and 250 MeV
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Figure 22. 2D gamma analysis of sagittal slice at isocenter comparing the study reference plan
to the plan corresponding to 140 kV and 250 MeV
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Chapter 3

3 Results and Discussion
3.1 Aim 1 (HU/RLSP determination and calibration curve creation)
The goal of the first specific aim was to measure the HU and RLSP of designated materials
and then create custom calibration curves to be used in treatment planning. The first step in
creating custom curves was to measure the HU of each material in the proton CT phantom
for each of three CT techniques: 80, 120, and 140 kV. The first step in this process was to
measure the constancy of the CT scanner over time and the results of this can be seen
below. Measurements were taken daily for five days and then weekly for a subsequent 5
weeks. The results are pictured below in Figure 23 with the standard deviation of each
material visualized in Figure 24.

Scanner HU Constancy
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-800.00
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-1000.00
-1200.00
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Scan Number

Figure 23. Constancy of HU values on MD Anderson CT simulation scanners
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Standard deviation of phantom materials
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Figure 24. HU variability of CT phantom materials

These figures show that the largest deviations occur in bone. This is expected due to the
high density of the material and potential for beam hardening or streaking artifacts. A
similarly high deviation is seen for air. This stability over time is comparable to that seen in
QA at PTC-H as well as in literature [33].

The resulting HU values measured at multiple CT energies can be seen below in Table 4.
Only minor differences in the HU of the low density materials (air and balsa wood) were
observed, but for the other materials, excluding water, the points of normalization,
differences in HU were observed between the 3 CT energies. The largest difference, up to
an approximately 80% difference, was observed between the 80 kV and the two other CT
techniques. The maximum percent change between 120 and 140 kV was observed for
polyethylene with a 17% change. Moyers reports a small change in RLSP due to nonstandard CT techniques at low atomic numbers that increases with increasing atomic
number [7]. We see this same increasing deviation as the density of material increases [34].

Table 4. Measured HU at three CT techniques
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HU
Material

80 kV

120 kV

140 kV

Air

-981.90 -982.79

-980.58

Balsa wood

-695.56 -693.48

-693.28

-85.29 -55.53

-47.62

Polyethylene
Water

3.55 2.00

2.69

Blue water

159.01 120.48

111.67

Presage®

191.09 152.72

143.53

Bone

757.61 571.17

528.69

In addition to HU, the RLSP was measured for each material in the CT phantom at each of
three proton energies: 140, 200, and 250 MeV. These results can be seen in Table 5 below.
The resulting variation in RLSP as a function of proton energy was very small. The maximum
difference was observed for the balsa wood material showing a 7.3% increase in the RLSP
going from 250 MeV to 140 MeV. As the density of the materials increased, the variation in
RLSP decreased to be less than 1%.

The HU for air listed in Table 4 were measured in the air hole of the proton CT phantom.
Literature has reported up to a 1.8% difference in HU of air measuring inside and outside a
phantom and this could therefore be an additional source of uncertainty in the HU
measurements [35].

These data in Table 5, except for the lung equivalent material of balsa wood, agree with the
data published by Moyer et al that reported an energy dependence of <1.2% for soft tissues
[7].

Balsa wood is used to simulate lung tissue the maximum difference in RLSP due to proton
energy in this material could be a cause for concern[36]. The data indicate larger differences
in RLSP that would result in larger changes in proton range, altering the dose distribution.
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This is relevant for the lung phantom and this material because of the possibility of larger
errors in the structure of interest during lung irradiations of this IROC-H phantom.

Table 5. Measured RLSP at three proton energies for the 120 kV CT technique
RLSP
Material

140 MeV

200 MeV

250 MeV

Air

0.000

0.000

0.000

Balsa wood

0.355

0.345

0.331

Polyethylene

1.014

1.016

0.996

Water

1.000

1.000

1.000

Blue water

1.068

1.067

1.067

Presage®

1.082

1.085

1.085

Bone

1.290

1.281

1.277

Proton CT calibration curves were created by plotting HU versus RLSP for all combinations
of CT technique and proton energy. These custom curves were compared to the calibration
curve currently used clinically by the Eclipse proton treatment planning system at UT MD
Anderson Cancer. This comparison is relevant because the currently used curve was created
with the same equipment used to create the custom calibration curves for this project.
Figure 25 below pictures the clinically used calibration curve as a reference compared to all
9 of the custom curves created for this experiment. The large dashed line depicts a 3%
difference from the clinical reference curve and the smaller dashed line depicts a 5%
difference from the clinical reference curve.
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CT Calibration Curves
1.6
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3% pos hu, pos sp
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1.2

0.95
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0.6
0.4

0.2
-1400.00 -1000.00

-600.00

0.0
-200.00

200.00

HU

600.00

1000.00

Figure 25. Custom CT calibration curves with clinical reference curve

As seen in Figure 25 above, the polyethylene material is the material with the largest
difference from the clinical reference. For each curve seen above polyethylene is the
material with HU ranging from -48 to -83. This data shows RLSP values for polyethylene
greater than unity, causing the CT calibration curves to not have constantly increasing
RLSPs. While this can be an issue for practical reasons with the treatment planning system,
this is consistent with data found in the literature and therefore not a cause for concern [7].
This figure can be reexamined without the effects of polyethylene in Figure 26 below.
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CT Calibration Curves
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Figure 26. Custom CT Calibration curves with clinical reference curve excluding polyethylene

With the exclusion of polyethylene, most points on the curve fall within the ±5% boundary.
It can be seen that at low CT techniques (80 kV) the curve begins to fall further away from
the reference at higher HU values. For a given material of any HU, the maximum difference
in predicted RLSP between the clinical reference curve and the custom curve is 12%. Due to
the Bragg peak associated with steep proton dose gradients, errors in proton dose delivery
could be significant if the edge of the peak lies close to an interface with a high density
material, as this data shows RLSP has a maximum deviation in high density materials such as
bone. This high deviation at low CT could pose a problem for institutions if they were
imaging patients under this very low CT technique and the patient had metal implants, for
example. In this scenario it would be recommended to the clinic to override high density
materials for treatment planning.

The custom calibration curve can also be visually compared to the “reference” curve
defined by this project as the curve created with 120 kV CT technique and 140 MeV proton
energy. This difference can be seen below in Figure 27. The 3% and 5% differences are
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defined from the reference curve for this study rather than the clinical reference curve
here.

CT Calibration Curves
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Figure 27. Custom CT Calibration curves with 120 kV/ 140 MeV reference curve including
polyethylene

When polyethylene is included, the curves stay within 3% difference of the 120 kV/140 MeV
reference curve pictured in Figure 27 to a much higher degree than the 3% difference line of
the clinical reference curve shown in Figure 25. The same drift of RLSP corresponding to low
kV (80 kV) away from the reference can be seen. For a given material of any HU, the
maximum difference in predicted RLSP between the study reference curve and the custom
curve is 7%, lower than that between the clinical reference curve and the custom curve.

An example of the modified calibration curves to be input into the Eclipse treatment
planning system is shown below in Figure 28. It is shown compared to the reference curve
currently used in the clinic at PTC-H.
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CT Calibration Curve
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Figure 28. CT Calibration Curve for Input into Eclipse Treatment Planning System Corresponding
to 120 kV CT Technique and 140 MeV Proton Energy

Additionally, the uncertainty in material thickness was examined to determine the possible
effect on RLSP that would translate to deposited dose. These results can be seen below in
Table 6.
Table 6. Effect of material thickness on RLSP
140 MeV

200 MeV

RLSP Difference RLSP Percent RLSP Difference RLSP Percent
Material
[MeV cm2/g]
Difference
[MeV cm2/g]
Difference
Polyethylene
0.001
0.140
0.001
0.140
Balsa wood
9.27E-05
0.026
9.00E-05
0.026
Blue water
0.000
0.012
0.000
0.012
HPV
0.001
0.115
0.001
0.115
Presage®
0.001
0.095
0.001
0.095

250 MeV
RLSP
RLSP Difference Percent
[MeV cm2/g]
Difference
0.001
0.140
8.63E-05
0.026
0.000
0.012
0.001
0.115
0.001
0.095

Table 6 shows that the uncertainty in the material thickness leads to a maximum change in
RLSP of 0.001 across all materials and proton energies. 0.001 is the smallest unit of RLSP
difference that the Eclipse treatment planning system can differentiate and therefore would
not lead to a meaningful change in dose distribution.
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3.2

Aim 2 (Creation of plans)
The goal of aim 2 was to incorporate the custom CT calibration curves into the Eclipse
treatment planning system to create 9 different treatment plans to evaluate their effects on
the resulting dose distributions to see if there were any measurable differences. The 9
different dose distributions were calculated by the planning system based on the given RLSP
provided by the custom curve and the subsequent calculated proton range and deposited
dose.

3.2.1 Dose Volume Histograms (DVH)
The DVHs for three organs (heart, lung, and target) for each plan was examined in
the treatment planning system and compared to clinical standards to assess the
quality of the treatment plan. The DVHs between the 9 plans were also compared
as a measure of differences due to the varying CT technique and different proton
energy. An example DVH of the plan corresponding to 120 kV CT technique and
140 MeV proton energy can be seen below in Figure 29. The remaining 8 DVH’s for
all plans can be found in the Appendix. In Figure 29, the dose to the heart is shown
in yellow, the dose to the lung is shown in blue, and the dose to the target is
shown in cyan. This color scheme is followed for all DVH’s shown for this study.
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Figure 29. Heart, lung, and target DVH of plan corresponding to 120 kV CT technique and 140
MeV proton energy

Based on the DVH in Figure 29 above, the 3 organ structures met the clinical
constraints and goals. The heart dose is very low, and remains so for all plans, and
is below clinical critical limits [37]. The target dose achieved its goal of >100% of
the prescription dose of 600 cGy and this too is consistent throughout all 9 plans.
However, the lung dose, as measured with the V20% (percent of the lung volume
receiving 20% of the prescription dose), varied slightly between plans as shown
below in Table 7.

Table 7. DVH of lung for various treatment plans
Plan [kV_MeV]

V20% [%]

80_140

24

80_200

25

80_250

26

120_140

24
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120_200

24

120_250

24

140_140

24

140_200

25

140_250

26

V20% is a metric describing the dose is a standard used clinically to predict lung
complications and is kept below 30-35% at MD Anderson Cancer Center for
treatment with radiation therapy alone [37][38]. All V20% values for plans in this
study are below this 40% threshold and these plans are therefore considered
acceptable. The variation noted in V20% between the different plans ranged from
24% to 26% with the reference lung treatment parameters of 120 kV/140 MeV
having a V20% of 24%. These data suggest that regardless of the proton beam
energy or CT technique used, the resulting proton dose distributions would not
impact the lung dose in any great amount.
3.2.2 HU Overrides

3.3 Aim 3 (Analysis of plan differences)
3.3.1 3D gamma analysis
A 3D gamma analysis, using the CERR software, was performed as described in
previous sections between the reference lung treatment plan corresponding to 120
kV CT technique and 140 MeV proton energy.

Recall that this study is examining the hypothesis that the variations in the
treatment plans caused by the different CT techniques and proton beam energy
RLSP values will reduce the percent of passing pixels by 10% using a gamma criteria
of ±3%/5mm. A threshold of 5% was used for both 3D and 2D gamma analyses.
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Shown below in Figure 30 are the results of the percent of pixels passing the 3D
gamma index criteria of ±3%/5mm for each of four contoured structures for each
of the 8 plans as compared to the 120 kV/140 MeV.

3D Gamma Analysis
100.5

% Passing Pixels

100
99.5
99
98.5
98
97.5
80_140

80_200

80_250 120_200 120_250 140_140 140_200 140_250

Body

Heart

Lung

Target

Figure 30. 3D gamma analysis of 120 kV/ 140 MeV treatment plan compared to all other
treatment plans created for this study with a gamma criteria of 3%/5mm

These 3D gamma analysis results are displayed for different contours in the plan.
The primary contour of interest is the Target contour as this is the section of the
phantom used for analysis in IROC-H audits using the proton lung phantom. As
shown above, every plan has a Target with a 100% rate of passing pixels. The
variation in CT technique and proton beam energy had no effect on the Target
dose. The lowest passing rate of pixels is found in the lung, likely due to the large
volume and heterogeneous nature of the lung material. However, this pass rate is
still very high, 98.4%, far below our hypothesized 10% reduction. Although not of
primary interest, the gamma evaluation of the Body and Heart contours are also
included in Figure 30 for reference with the goal of pinpointing any failing pixels.
An example of the spatial representation of this gamma analysis with a ±3%/5mm
criteria can be seen in Figure 31 below. While not included in the ROI of the
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gamma analysis, there were areas at the distal end of each proton beam that
showed some disagreement. This was to be expected due to the observed
differences in the RLSPs as a function of beam energy for the low density tissue
substitutes. While there appear to be some localized differences, the impact on the
overall lung dose is minimal and has no impact on the Target dose. A full set of
visual representations of these gamma analyses at isocenter can be seen in the
Appendix.

Figure 31. Gamma analysis at isocenter of plan corresponding to study lung reference curve
compared with plan corresponding to 80 kV and 250 MeV with gamma criteria 3%/5mm

Because the percent of passing pixels was so high for the hypothesis criteria, there
was interest in the effects of variable gamma criteria. Shown below in Figure 32 are
the results of a gamma analysis performed on the same plans as described
previously, but with an extremely tight gamma criteria of ±1%/1mm.
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Figure 32. 3D gamma analysis of 120 kV/ 140 MeV treatment plan compared to all other
treatment plans created for this study with a gamma criteria of 1%/1mm

From these gamma tests, it can be seen that although the majority of the Targets
maintains a 100% pixel passing rate (one Target had a percent of passing pixels of
99.5%), the lung becomes a good representation of the change experienced due to
the varying treatment plans. From this it can be seen that the lowest passing rate is
associated with the 250 MeV proton energy, for both 80 kV and 140 kV, yet no
plans resulted in greater than a 5.6% change, still less than the hypothesized 10%
change. This lack of dependence on CT technique is in contrast to the CT calibration
curves alone, which showed a large difference at a low CT technique. The lower
pass rate also seen here at the highest proton energy, 250 MeV, for all CT
techniques, is not reflected in the CT calibration curve differences noted earlier. It
is possible that the percent of pixels passing at 1%/1mm criteria is not an
appropriate metric when comparing the variations in the CT calibration curves and
the resulting treatment planning system calculated dose distributions. There are
approximations in the planning system dose calculations that possibly cannot
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distinguish differences at the 1%/1mm level. These approximations would be
especially problematic for such tight criteria if registering of images was involved.

An example of the spatial representation of this gamma analysis with 1%/1mm
criteria at the isocenter can be seen in Figure 33 below. A full set of visual
representations of these gamma analyses at isocenter can be seen in the Appendix.

Figure 33. Gamma analysis at isocenter of plan corresponding to study reference curve
compared with plan corresponding to 80 kV and 250 MeV with gamma criteria 1%/1mm

The gamma criteria were then further tightened with the goal of approaching the
point of failing, defined as <90% of passing pixels. This test was only performed for
the study reference curve compared to the curve corresponding to 80 kV and 250
MeV due to its already established lower passing rate. With the criteria tightened
to 0.5%/0.5mm, the results of a gamma test for all contours in this comparison are
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shown below in Figure 34. Even with this unrealistic gamma criteria, the difference
in pixels did not ever exceed 10%. Varying the CT technique and proton beam
energy did not negatively impact any of the comparisons for any of the 9 plans.

3D Gamma Analysis
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Figure 34. Results of 3D gamma analysis of plan using study reference curve compared to the
curve corresponding to 80 kV CT technique and 250 MeV proton energy

An example of the spatial representation of this gamma analysis with 0.5%/0.5mm
criteria at the isocenter can be seen in Figure 35 below.
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Figure 35. Gamma analysis at isocenter of plan corresponding to study reference curve
compared with plan corresponding to 80 kV and 250 MeV with gamma criteria 0.5%/0.5mm

3.3.2 2D gamma analysis
Due to the very high pass rates of the 3D gamma analysis the difference between
3D analyses and 2D analyses was investigated.
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Figure 36. 2D gamma analysis of 120 kV/ 140 MeV treatment plan compared to all other
treatment plans created for this study with a gamma criteria of 3%/5mm

Recall that this gamma analysis was done for all three planes, axial, coronal and
sagittal, comparing the study lung reference plan (120 kV/140 MeV) to all other
plans created for the study. As shown in Figure 36, it is possible to see that the
lowest number of passing pixels using a gamma index criteria of ±3%/5mm occurs
for the comparison between the study reference plan and the plan corresponding
to 140 kV and 250 MeV, contradicting the maximum difference seen in the CT
calibration curves at a low 80 kV technique, but consistent with the results of the
3D gamma analysis. At the hypothesis gamma criteria of 3%/5mm, a spatial
representation of this gamma analysis can be seen below in Figures 37-39 for the
three spatial planes. The only differences noted are at the distal ends of each
treatment beam because of the measured differences in lung RLSPs. The remaining
2D gamma representations and profiles can be seen in the Appendix.
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Figure 37. 2D gamma analysis of axial slice at isocenter comparing the study reference plan to
the plan corresponding to 140 kV and 250 MeV with gamma criteria of 3%/5mm

Figure 38. 2D gamma analysis of coronal slice at isocenter comparing the study reference plan
to the plan corresponding to 140 kV and 250 MeV with gamma criteria of 3%/5mm
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Figure 39. 2D gamma analysis of sagittal slice at isocenter comparing the study reference plan
to the plan corresponding to 140 kV and 250 MeV with gamma criteria of 3%/5mm

The 2D gamma analysis was repeated with a tighter gamma criteria, as was performed
with the 3D analysis. The plan with the maximum difference, as determined by the
percent of passing pixels using a ±3%/5mm gamma index analysis, is seen in Figure 36
to be the plan corresponding to 140 kV and 250 MeV. A threshold of 5% was used. The
gamma analysis was also run with the tightened criteria of 1%/1mm with the same
threshold for the same two plans and the results are seen below in Figures 40-42. The
actual % of pixels passing the 1%/1mm criteria are listed in Table 8.
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Figure 40. 2D gamma analysis of axial slice at isocenter comparing study reference plan to the
plan corresponding to 140 kV and 250 MeV with gamma criteria of 1%/1mm

Figure 41. 2D gamma analysis of coronal slice at isocenter comparing study reference plan to
the plan corresponding to 140 kV and 250 MeV with gamma criteria of 1%/1mm
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Figure 42. 2D gamma analysis of sagittal slice at isocenter comparing study reference plan to
the plan corresponding to 140 kV and 250 MeV with gamma criteria of 1%/1mm

This tightened criteria of 1%/1mm is quantified in Table 8 below.

Table 8. 2D Gamma results for study reference plan compared to 140 kV and 250 MeV plan with
gamma criteria of 1%/1mm
% Passing
Pixels
Axial

96.22

Coronal

97.91

Sagittal

97.58

A gamma criteria of 1%/1mm is much tighter than that used clinically or by IROC-H.
Even at this very tight criteria, the passing pixel percentage was well above the
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hypothesized 90% needed for the plan to pass, indicating a low level of influence due to
variable CT technique and proton energy in the creation of CT calibration curves even
using a 2D gamma analysis.
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Chapter 4
4 Conclusions
4.1 Meeting of specific aims

The goal of this project was to understand the uncertainty in the proton CT calibration
curves at proton institutions and its influence on the credentialing and auditing process
(E2E anthropomorphic QA phantom irradiation) performed by IROC-H that might stem
from variable CT technique and proton energy. This project further looked at how this
uncertainty might translate to uncertainties in dose distributions. The hypothesis of this
project was to determine if this variable CT technique and proton energy would lead to
a change in dose distribution resulting in more than 10% of failing pixels with a gamma
analysis criteria of ±3%/5mm.

The first specific aim was to measure the HU and RLSP of phantom materials and create
custom calibration curves. This was accomplished with the proton CT phantom
containing 6 proton equivalent materials currently used by IROC-H on proton institution
site visits. All of the custom curves were compared to the clinical reference curve used
at MD Anderson’s PTC-H and the reference curve (120 kV and 140 MeV) used for this
study. It was found that the maximum difference in predicted RLSP between the clinical
reference curve and the custom curves was no more than 12%. The maximum
difference in predicted RLSP between the study’s reference curve and the custom
curves was 7%. This completed specific aim one and laid the ground work for aims two
and three as well as provided as initial reference when comparing dose differences.

The second specific aim involved the creation of 9 treatment plans for IROC-H’s proton
lung phantom and was accomplished simultaneously with the first part of specific aim
three which required uploading the custom calibration curves into the Eclipse
treatment planning system and calculating the plans, each using a different proton CT
calibration curve. This was accomplished through the beam administration functions of
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Eclipse as described in previous chapters. Once the custom curves were uploaded and
assigned to treatment plans it was possible to calculate the plans and get dose
distributions specific to each set of parameters.

Specific aim 3 was the evaluation and analysis of the treatment plans created in specific
aim two. Both 3D and 2D gamma analyses were performed to evaluate the hypothesis
as described in previous chapters. The hypothesis stated that the passing rate must be
reduced by more than 10% passing pixels at a gamma criteria of 3%/5mm, meaning a
pass rate of less than 90% for any treatment plan compared to the study’s reference
plan. At this gamma criteria, the percent of passing pixels for the Target structure was
100%. Zero percent of pixels failing implies that the changing plans from the various CT
techniques and/or proton beam energy have no substantial effect on the dose
distribution. Following from this, we can conclude that the use of proton CT calibration
curves with variable CT technique and proton energy is not a substantial source of
uncertainty in IROC-H’s end to end (E2E) credentialing and auditing QA processes that
use the proton anatomic phantoms and is not contributing to any institution failing a
proton audit.

This refutes the hypothesis defined for this study that states:

Variations in CT technique and proton energy will alter the delivered dose distributions
of typical proton treatments by reducing the percent of passing pixels by 10% using a
gamma analysis criteria of ±3%/5 mm as measured using a heterogeneous proton QA
phantom.

4.2

Clinical significance
IROC-H provides QA services to institutions participating in NCI funded clinical trials
involving proton therapy. The purpose of IROC-H is to ensure that institutions are
delivering accurate and comparable doses, which is accomplished in part by phantom
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dosimetry audits. In this process it is critical for IROC-H to understand the potential
uncertainties in the QA phantoms and in the E2E process in order to provide accurate
feedback. This study adds to the understanding of the uncertainty in this process with
the goal of improving institution feedback and therefore improving clinical trial data
and cancer care.
4.3

Future work
The results of this project resulted in conclusions that rejected the stated hypothesis
and therefore open the door for additional studies to address the problem described in
Chapter 1. The increased failure rate of institutions participating in proton QA through
IROC-H continues to have an unknown source and steps should be taken in the future
to investigate this uncertainty further.

It could be valuable to determine how this uncertainty is seen in a scanning beam,
although expected differences would be low because the measurement of RLSP would
remain consistent. Additionally the addition of motion, frequently used in IROC-H
proton audits with the lung phantom, could also add a level of uncertainty not
evaluated in this project.

The continued presence of an uncertainty in the auditing process of IROC-H can lead to
additional institution failures and reduces the reliability of the QA services provided by
IROC-H and may negatively affect the availability and quality of data provided to NCI
funded clinical trials.
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Chapter 5

5 Appendix
5.1 Incline

Figure 43. Depth Dose Measured by Zebra at 140 MeV for Various Materials
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Figure 44. Depth Dose Measured by Zebra at 200 MeV for Various Materials

Figure 45. Depth Dose Measured by Zebra at 250 MeV for Various Materials
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5.2

Custom curves
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Figure 46. CT Calibration Curve with HU Corresponding to 80 kV and RLSP corresponding to 140
MeV

80 kV, 200 MeV
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0.0
-1,200

-800

-400

0

400

800

Figure 47. CT Calibration Curve with HU Corresponding to 80 kV and RLSP corresponding to 200
MeV
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Figure 48. CT Calibration Curve with HU Corresponding to 80 kV and RLSP corresponding to 250
MeV
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Figure 49. CT Calibration Curve with HU Corresponding to 120 kV and RLSP corresponding to 140
MeV
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Figure 50. CT Calibration Curve with HU Corresponding to 120 kV and RLSP corresponding to 200
MeV
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Figure 51. CT Calibration Curve with HU Corresponding to 120 kV and RLSP corresponding to 250
MeV
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Figure 52. CT Calibration Curve with HU Corresponding to 140 kV and RLSP corresponding to 140
MeV
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Figure 53. CT Calibration Curve with HU Corresponding to 140 kV and RLSP corresponding to 200
MeV
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Figure 54. CT Calibration Curve with HU Corresponding to 140 kV and RLSP corresponding to 250
MeV
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Figure 55. CT Calibration Curves with HU Corresponding to 80 kV
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Figure 56. CT Calibration Curves with HU Corresponding to 120 kV
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Figure 57. CT Calibration Curves with HU Corresponding to 140 kV
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Figure 58. CT Calibration Curves with RLSP Corresponding to 140 MeV
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Figure 59. CT Calibration Curves with RLSP Corresponding to 200 MeV
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Figure 60. CT Calibration Curves with RLSP Corresponding to 250 MeV

5.3

Dose at Isocenter
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Figure 61. Dose Distribution at Isocenter of Plan Using CT Calibration Curve Corresponding to 80
kV CT Technique and 140 MeV Proton Energy
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Figure 62. Dose Distribution at Isocenter of Plan Using CT Calibration Curve Corresponding to 80
kV CT Technique and 200 MeV Proton Energy
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Figure 63. Dose Distribution at Isocenter of Plan Using CT Calibration Curve Corresponding to 80
kV CT Technique and 250 MeV Proton Energy
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Figure 64. Dose Distribution at Isocenter of Plan Using CT Calibration Curve Corresponding to
120 kV CT Technique and 140 MeV Proton Energy
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Figure 65. Dose Distribution at Isocenter of Plan Using CT Calibration Curve Corresponding to
120 kV CT Technique and 200 MeV Proton Energy
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Figure 66. Dose Distribution at Isocenter of Plan Using CT Calibration Curve Corresponding to
120 kV CT Technique and 250 MeV Proton Energy
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Figure 67. Dose Distribution at Isocenter of Plan Using CT Calibration Curve Corresponding to
140 kV CT Technique and 140 MeV Proton Energy
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Figure 68. Dose Distribution at Isocenter of Plan Using CT Calibration Curve Corresponding to
140 kV CT Technique and 200 MeV Proton Energy
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Figure 69. Dose Distribution at Isocenter of Plan Using CT Calibration Curve Corresponding to
140 kV CT Technique and 250 MeV Proton Energy

5.4

CERR Dose Distributions
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Figure 70. Dose smear provided by CERR for the plan corresponding to 80 kV CT technique and
140 MeV proton energy
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Figure 71. Dose smear provided by CERR for the plan corresponding to 80 kV CT technique and
200 MeV proton energy
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Figure 72. Dose smear provided by CERR for the plan corresponding to 80 kV CT technique and
250 MeV proton energy
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Figure 73. Dose smear provided by CERR for the plan corresponding to 120 kV CT technique and
140 MeV proton energy
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Figure 74. Dose smear provided by CERR for the plan corresponding to 120 kV CT technique and
200 MeV proton energy
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Figure 75. Dose smear provided by CERR for the plan corresponding to 120 kV CT technique and
250 MeV proton energy
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Figure 76. Dose smear provided by CERR for the plan corresponding to 140 kV CT technique and
140 MeV proton energy
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Figure 77. Dose smear provided by CERR for the plan corresponding to 140 kV CT technique and
200 MeV proton energy
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Figure 78. Dose smear provided by CERR for the plan corresponding to 140 kV CT technique and
250 MeV proton energy

5.5

CERR 3D Gamma Analysis
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Figure 79. Gamma analysis at isocenter of plan corresponding to study reference curve
compared with plan corresponding to 80 kV and 140 MeV with gamma criteria 3%/5mm
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Figure 80. Gamma analysis at isocenter of plan corresponding to study reference curve
compared with plan corresponding to 80 kV and 200 MeV with gamma criteria 3%/5mm
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Figure 81. Gamma analysis at isocenter of plan corresponding to study reference curve
compared with plan corresponding to 80 kV and 250 MeV with gamma criteria 3%/5mm
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Figure 82. Gamma analysis at isocenter of plan corresponding to study reference curve
compared with plan corresponding to 120 kV and 200 MeV with gamma criteria 3%/5mm
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Figure 83. Gamma analysis at isocenter of plan corresponding to study reference curve
compared with plan corresponding to 120 kV and 250 MeV with gamma criteria 3%/5mm
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Figure 84. Gamma analysis at isocenter of plan corresponding to study reference curve
compared with plan corresponding to 140 kV and 140 MeV with gamma criteria 3%/5mm
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Figure 85. Gamma analysis at isocenter of plan corresponding to study reference curve
compared with plan corresponding to 140 kV and 200 MeV with gamma criteria 3%/5mm
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Figure 86. Gamma analysis at isocenter of plan corresponding to study reference curve
compared with plan corresponding to 140 kV and 250 MeV with gamma criteria 3%/5mm

121

Figure 87. Gamma analysis at isocenter of plan corresponding to study reference curve
compared with plan corresponding to 80 kV and 140 MeV with gamma criteria 1%/1mm
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Figure 88. Gamma analysis at isocenter of plan corresponding to study reference curve
compared with plan corresponding to 80 kV and 200 MeV with gamma criteria 1%/1mm
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Figure 89. Gamma analysis at isocenter of plan corresponding to study reference curve
compared with plan corresponding to 80 kV and 250 MeV with gamma criteria 1%/1mm
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Figure 90. Gamma analysis at isocenter of plan corresponding to study reference curve
compared with plan corresponding to 120 kV and 200 MeV with gamma criteria 1%/1mm
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Figure 91. Gamma analysis at isocenter of plan corresponding to study reference curve
compared with plan corresponding to 120 kV and 250 MeV with gamma criteria 1%/1mm
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Figure 92. Gamma analysis at isocenter of plan corresponding to study reference curve
compared with plan corresponding to 140 kV and 140 MeV with gamma criteria 1%/1mm
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Figure 93. Gamma analysis at isocenter of plan corresponding to study reference curve
compared with plan corresponding to 140 kV and 200 MeV with gamma criteria 1%/1mm
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Figure 94. Gamma analysis at isocenter of plan corresponding to study reference curve
compared with plan corresponding to 140 kV and 250 MeV with gamma criteria 1%/1mm

5.6 2D Gamma Analysis
5.6.1 Axial planes
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Figure 95. 2D gamma analysis of axial slice at isocenter comparing the study reference plan to
the plan corresponding to 80 kV and 140 MeV with gamma criteria of 3%/5mm

Figure 96. 2D gamma analysis of axial slice at isocenter comparing the study reference plan to
the plan corresponding to 80 kV and 200 MeV with gamma criteria of 3%/5mm
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Figure 97. 2D gamma analysis of axial slice at isocenter comparing the study reference plan to
the plan corresponding to 80 kV and 250 MeV with gamma criteria of 3%/5mm

Figure 98. 2D gamma analysis of axial slice at isocenter comparing the study reference plan to
the plan corresponding to 120 kV and 200 MeV with gamma criteria of 3%/5mm
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Figure 99. 2D gamma analysis of axial slice at isocenter comparing the study reference plan to
the plan corresponding to 120 kV and 250 MeV with gamma criteria of 3%/5mm

Figure 100. 2D gamma analysis of axial slice at isocenter comparing the study reference plan to
the plan corresponding to 140 kV and 140 MeV with gamma criteria of 3%/5mm
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Figure 101. 2D gamma analysis of axial slice at isocenter comparing the study reference plan to
the plan corresponding to 140 kV and 200 MeV with gamma criteria of 3%/5mm

Figure 102. 2D gamma analysis of axial slice at isocenter comparing the study reference plan to
the plan corresponding to 140 kV and 250 MeV with gamma criteria of 3%/5mm
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5.6.2 Coronal planes

Figure 103. 2D gamma analysis of coronal slice at isocenter comparing the study reference plan
to the plan corresponding to 80 kV and 140 MeV with gamma criteria of 3%/5mm

Figure 104. 2D gamma analysis of coronal slice at isocenter comparing the study reference plan
to the plan corresponding to 80 kV and 200 MeV with gamma criteria of 3%/5mm
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Figure 105. 2D gamma analysis of coronal slice at isocenter comparing the study reference plan
to the plan corresponding to 80 kV and 250 MeV with gamma criteria of 3%/5mm

Figure 106. 2D gamma analysis of coronal slice at isocenter comparing the study reference plan
to the plan corresponding to 120 kV and 200 MeV with gamma criteria of 3%/5mm
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Figure 107. 2D gamma analysis of coronal slice at isocenter comparing the study reference plan
to the plan corresponding to 120 kV and 250 MeV with gamma criteria of 3%/5mm

Figure 108. 2D gamma analysis of coronal slice at isocenter comparing the study reference plan
to the plan corresponding to 140 kV and 140 MeV with gamma criteria of 3%/5mm
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Figure 109. 2D gamma analysis of coronal slice at isocenter comparing the study reference plan
to the plan corresponding to 140 kV and 200 MeV with gamma criteria of 3%/5mm

Figure 110. 2D gamma analysis of coronal slice at isocenter comparing the study reference plan
to the plan corresponding to 140 kV and 250 MeV with gamma criteria of 3%/5mm
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5.6.3 Sagittal planes

Figure 111. 2D gamma analysis of sagittal slice at isocenter comparing the study reference plan
to the plan corresponding to 80 kV and 140 MeV with gamma criteria of 3%/5mm
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Figure 112. 2D gamma analysis of sagittal slice at isocenter comparing the study reference plan
to the plan corresponding to 80 kV and 200 MeV with gamma criteria of 3%/5mm

Figure 113. 2D gamma analysis of sagittal slice at isocenter comparing the study reference plan
to the plan corresponding to 80 kV and 250 MeV with gamma criteria of 3%/5mm
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Figure 114. 2D gamma analysis of sagittal slice at isocenter comparing the study reference plan
to the plan corresponding to 120 kV and 200 MeV with gamma criteria of 3%/5mm

Figure 115. 2D gamma analysis of sagittal slice at isocenter comparing the study reference plan
to the plan corresponding to 120 kV and 250 MeV with gamma criteria of 3%/5mm
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Figure 116. 2D gamma analysis of sagittal slice at isocenter comparing the study reference plan
to the plan corresponding to 140 kV and 140 MeV with gamma criteria of 3%/5mm

Figure 117. 2D gamma analysis of sagittal slice at isocenter comparing the study reference plan
to the plan corresponding to 140 kV and 200 MeV with gamma criteria of 3%/5mm
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Figure 118. 2D gamma analysis of sagittal slice at isocenter comparing the study reference plan
to the plan corresponding to 140 kV and 250 MeV with gamma criteria of 3%/5mm
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